Folotyn is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat peripheral T-cell lymphoma (PTCL) that has relapsed or failed to respond to other drugs. Folotyn is also referred to by its drug name, pralatrexate.
Folotyn is an anticancer drug. Folotyn is an antifolate and an antimetabolite. Folotyn is believed to work by killing cancer cells and slowing their growth.
How do I take it?
Folotyn is administered by intravenous injection once a week for six weeks.
Folotyn comes in the form of a single-dose vial.
The FDA-approved label for Folotyn lists common side effects including fever, fatigue, nausea, dehydration, trouble breathing, low blood cell counts, and mucositis – inflammation of the mucous membranes that line the gastrointestinal tract.
Rare but serious side effects listed for Folotyn include sepsis (life-threatening reaction to infection), liver damage, fetal harm in pregnant women, severe skin reactions, and tumor lysis syndrome (a potentially fatal metabolic condition caused when many cancer cells die at the same time).
For more details about this treatment, visit:
Folotyn — Acrotech Biopharma
Treatment for Aggressive NHL Subtypes — Leukemia & Lymphoma Society